Angiogenesis — Tumour Blood Vessel Growth

Angiogenesis is a strictly regulated biological sequence involving endothelial cell activation, enzymatic degradation of the vascular basement membrane, cellular migration, proliferation, and lumen formation. Under normal physiological circumstances, pro-angiogenic and anti-angiogenic factors exist in precise equilibrium to prevent unregulated vascular sprouting.

In malignant neoplasia, tumours outgrow their passive oxygen diffusion limits (approximately 1 to 2 millimetres), developing localized hypoxia. In response, hypoxia-inducible factors trigger the continuous, pathological overexpression of pro-angiogenic signalling proteins, most notably vascular endothelial growth factor (VEGF). This phenomenon, known as the 'angiogenic switch', generates an aberrant, disorganized, and hyperpermeable capillary network that fuels tumour expansion and facilitates haematogenous metastatic dissemination.

Recognising the role of angiogenesis helps patients understand how anti-angiogenic targeted therapies function. Instead of directly poisoning malignant cells like traditional chemotherapy, anti-angiogenic agents choke off the tumour's blood supply. This targeted mechanism comes with a distinct profile of manageable side effects, such as hypertension, that require dedicated monitoring rather than standard chemotherapy-related toxicities.

Angiogenesis itself is not typically quantified by routine individual blood biomarkers in clinical practice, though researchers measure circulating VEGF levels. Instead, oncologists assess its functional activity via contrast-enhanced CT, MRI, or PET scans, which reflect tumour vascularity and perfusion. Tumour tissue may also be examined immunohistochemically for microvessel density or related genetic alterations like VHL mutations.

Angiogenesis is relevant to almost all solid tumours. It is a critical focus in renal cell carcinoma (kidney cancer), colorectal cancer, hepatocellular carcinoma (liver cancer), and non-small cell lung cancer. It also plays an important role in glioblastoma, ovarian cancer, and cervical cancer, where anti-angiogenic agents are routinely integrated into standard systemic therapy combinations.

Understanding angiogenesis directly informs the use of anti-angiogenic therapies. These include monoclonal antibodies (such as bevacizumab) that bind and neutralize VEGF ligands, as well as oral tyrosine kinase inhibitors (such as sunitinib, pazopanib, or lenvatinib) that block intracellular vascular receptors. These therapies are frequently combined with chemotherapy or immunotherapy to enhance drug delivery and heighten immune-mediated tumour elimination.